

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

Lu-99

RRID:CVCL_3015

Type: Cell Line

Proper Citation

RRID:CVCL_3015

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3015

Proper Citation: RRID:CVCL_3015

Description: Cell line Lu-99 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung giant cell carcinoma

Defining Citation: [PMID:3935627](#), [PMID:9290701](#), [PMID:11005564](#), [PMID:12569360](#), [PMID:16105816](#), [PMID:22313637](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:38639832](#)

Comments: Population: Japanese and Korean., Part of: NCI RAS program mutant KRAS cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Lu-99

Synonyms: LU-99, Lu 99, Lu99, LU99, C-Lu99

Cross References: BTO:BTO_0006141, CLO:CLO_0050038, ArrayExpress:E-MTAB-2770, BioSample:SAMN03471066, BioSample:SAMN10987825, cancercellines:CVCL_3015, Cell_Model_Passport:SIDM00546, ChEMBL-Cells:ChEMBL3308600, ChEMBL-Targets:ChEMBL614651, Cosmic:801578, Cosmic:808503, Cosmic:844828, Cosmic:876174, Cosmic:946068, Cosmic:1048224, Cosmic:1571756, Cosmic:1656907, Cosmic:2125270, DepMap:ACH-000444, GEO:GSM887283, GEO:GSM888358, IARC_TP53:30114, JCRB:JCRB0080,

LiGeA:CCLE_430, Progenetix:CVCL_3015, PubChem_Cell_line:CVCL_3015, RCB:RCB1900, TKG:TKG 0495, Wikidata:Q54903211

ID: CVCL_3015

Record Creation Time: 20220427T220737+0000

Record Last Update: 20260904T014554+0000

Ratings and Alerts

No rating or validation information has been found for Lu-99.

No alerts have been found for Lu-99.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(6), 1069.

Knoll N, et al. (2025) CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. Cancer research, 85(18), 3518.

Engstrom LD, et al. (2023) MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer discovery, 13(11), 2412.

Kofink C, et al. (2022) A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nature communications, 13(1), 5969.

Gurtner K, et al. (2020) Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. International journal of cancer, 147(2), 472.